Twist Bioscience Corporation (NASDAQ: TWST) reported Q4 EPS of ($0.96), $0.11 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $15.7 million versus the consensus estimate of $14.06 million.

GUIDANCE:

Twist Bioscience Corporation sees FY2020 revenue of $80-84 million, versus the consensus of $80.15 million.

• Revenue from Ginkgo Bioworks expected to be approximately $10 million
• Synbio revenue excluding Ginkgo Bioworks is expected to be in the range of $32 to $33 million
• NGS revenue is estimated to be in the range of $37 to $40 million
• Biopharma revenue is estimated to be approximately $1 million

Twist Bioscience Corporation sees Q1 2020 revenue of $15-16.5 million, versus the consensus of $15.92 million.

• Net loss expected in the range of $31 million to $32 million

For earnings history and earnings-related data on Twist Bioscience Corporation (TWST) click here.